News Sections
Lilly's Rheumatoid Arthritis Pill Rejected By Regulators
Updated April 16, 2017 10:43 AM | Filed under: Health
 Print    Archive    RSS

(INDIANAPOLIS) - Eli Lilly says U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker's second drug development setback since November.

The Food and Drug Administration said in a letter to the company that additional data from patient tests would be needed to better understand safety concerns and to determine the most appropriate doses, Lilly announced Friday. Lilly said it will work with the FDA on a plan to eventually get the drug, baracitinib, approved for U.S. patients.

In November, Lilly's experimental Alzheimer's medicine flopped in a closely watched patient test.

The drug, which has the proposed brand name Olumiant and is approved for use in Europe, was expected to be a big seller in part because most other new rheumatoid arthritis drugs are injected.

« Previous Article
Next Article »

 Print    Archive    RSS

Have a question or comment about a news story? Send it to

Advertise with 1340 AM WBIW
Find more about Weather in Bedford, IN
Advertise with 1340 AM WBIW

1340 AM WBIW, Bedford's Place To Talk. Serving Lawrence and surrounding counties since 1948!

© 2018 Ad-Venture Media, Inc. All Rights Reserved. and Listen Live Powered by HPC

Advertise  |  Careers  |  Contests  |  About  |  Feedback  |  Public File